source
- Apnimed announces IPO plans while FDA reviews its sleep-apnea therapyApnimed, a Cambridge, Massachusetts biotech, disclosed that it will pursue an initial public offering on Nasdaq. The move comes as the company’s lead sleep‑apnea candidate is under review by the U…
- FDA resumes publishing pharma rejection letters, posting 14 new CRLsThe FDA announced on Friday that it has posted fourteen new complete response letters (CRLs) to pharmaceutical companies on its website. This marks a return to the agency’s regular practice of mak…